C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis?
Cora N. Sternberg,D. Raghaven,Y. Ohi,Dean F. Bajorin,H Herr T Kato,M. Kuroda,Chris Logothetis,Howard I. Scher,Ted A.W. Splinter,AT Oosterom +9 more
TL;DR: This paper will attempt to address some of the important issues and questions surrounding the combination of chemotherapy and definitive local therapy in the treatment of muscle-invasive bladder cancer.
Journal ArticleDOI
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer
Nicholas J. Vogelzang,Karim Fizazi,John M. Burke,Ronald de Wit,Joaquim Bellmunt,Thomas E. Hutson,Edward J. Crane,William R. Berry,Kevin Doner,John D. Hainsworth,Paweł Wiechno,Kejian Liu,Michelle Waldman,Anita Gandhi,Debora Barton,Ulf Jungnelius,Abderrahim Fandi,Cora N. Sternberg,Daniel P. Petrylak +18 more
TL;DR: This study in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy, with or without lenalidomide, showed that patient survival was best predicted by circulating tumor cell count at the start of treatment.
Journal ArticleDOI
CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.
Hans J. Hammers,Elizabeth R. Plimack,Cora N. Sternberg,David F. McDermott,James Larkin,Alain Ravaud,Brian I. Rini,Padmanee Sharma,Prabhu Bhagavatheeswaran,Paul Gagnier,Robert J. Motzer +10 more
TL;DR: Therapeutic options have improved outcomes for patients with metastatic renal cell carcinoma (mRCC) and Nivolumab, a fully human IgG4 programmed cell death-1 immune checkpoin...
Journal ArticleDOI
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Silke Gillessen,Andrew J. Armstrong,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Anders Bjartell,Alberto Bossi,Alberto Briganti,Robert G. Bristow,Muhammad Bulbul,Orazio Caffo,Kim N. Chi,Caroline S. Clarke,Noel W. Clarke,Ian D. Davis,Johann S. de Bono,Ignacio Duran,Rosalind A. Eeles,Eleni Efstathiou,Jason A. Efstathiou,O. Ekeke,Christopher H. Evans,Stefano Fanti,Felix Y. Feng,Karim Fizazi,Mark Frydenberg,Daniel J. George,Martin E. Gleave,Susan Halabi,D. Heinrich,C. Higano,Michael S Hofman,Maha Hussain,Nicholas D. James,Robert Jones,Ravindran Kanesvaran,Raja B. Khauli,Laurence Klotz,Raya Leibowitz,Christopher J. Logothetis,Fernando C. Maluf,Robin Millman,Alicia K. Morgans,Michael J. Morris,Nicolas Mottet,Hind Mrabti,Declan G. Murphy,Vedang Murthy,William Oh,Piet Ost,Joe M. O'Sullivan,Anwar R. Padhani,Chris Parker,Darren M.C. Poon,Colin C. Pritchard,Danny M. Rabah,Dana E. Rathkopf,Robert E. Reiter,M.L. Rubin,Charles J. Ryan,Fred Saad,Juan Pablo Sade,Oliver Sartor,Howard I. Scher,Neal D. Shore,Iwona Skoneczna,Eric J. Small,Matthew R. Smith,Howard R. Soule,Daniel E. Spratt,Cora N. Sternberg,H. Suzuki,Christopher Sweeney,Matthew R. Sydes,Mary-Ellen Taplin,Derya Tilki,Bertrand Tombal,Levent Türkeri,Hiroji Uemura,Hirotsugu Uemura,Inge M. van Oort,Kosj Yamoah,Dingwei Ye,Almudena Zapatero,Aurelius Omlin +84 more
TL;DR: The 2019 Advanced Prostate Cancer Consensus Conference (APCCC) as mentioned in this paper addressed three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood.
Journal ArticleDOI
Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
Matthew R. Smith,Johann S. de Bono,Cora N. Sternberg,Sylvestre Le Moulec,Stéphane Oudard,Ugo De Giorgi,Michael Krainer,Andre M. Bergman,Wolfgang Hoelzer,Ronald de Wit,Martin Boegemann,Fred Saad,Giorgio Cruciani,Antoine Thiery Vuillemin,Susan Feyerabend,Kurt Miller,D. Ramies,Colin Hessel,Aaron Weitzman,Karim Fizazi +19 more
TL;DR: COMET-1 compared the effects of Cabo versus Pred on overall survival (OS) in men with progressive mCRPC and prior D and A and/or E in a randomized, double-blind, controlled phase 3 study.